# Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM

> **NCT03673826** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland** · enrollment: 58 (actual)

## Conditions studied

- Smouldering Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT03673826
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-19
- **Primary completion:** 2024-08
- **Final completion:** 2028-12
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03673826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03673826, "Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03673826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*